• Whitehawk Therapeutics disclosed two real-world analyses backing MUC16 as an ovarian cancer ADC target, slated for presentation at IGCS 2026.
• Data indicated MUC16 levels stayed broadly stable through standard treatments, supporting use in earlier-line combinations or relapsed settings.
• A separate analysis linked high MUC16 expression with worse real-world survival in high-grade serous ovarian carcinoma, supporting its prognostic relevance.
• Findings underpin development of HWK-016, a MUC16-directed ADC now in a Phase 1 trial in advanced ovarian and endometrial cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60918) on October 01, 2026, and is solely responsible for the information contained therein.